Edouard Randriamalala

Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma

Philippe Moreau, Hervé Avet‐Loiseau, Thierry Façon et al. · Blood · 2011 · 302 citations

Medicine, Hematology, Oncology +17

Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myélome (IFM)

Murielle Roussel, Philippe Moreau, Anne Huynh et al. · Blood · 2009 · 171 citations · Full text

Medicine, Hematology, Oncology +17

Minor clone provides a reservoir for relapse in multiple myeloma

Florence Magrangeas, Hervé Avet‐Loiseau, Wilfried Gouraud et al. · Leukemia · 2012 · 121 citations

Medicine, Hematology, Oncology +14

Addition of Gemtuzumab Ozogamycin to Chemotherapy Improves Event-Free Survival but Not Overall Survival of AML Patients with Intermediate Cytogenetics Not Eligible for Allogeneic Transplantation. Results of the GOELAMS AML 2006 IR Study

Jacques Delaunay, Christian Récher, Arnaud Pigneux et al. · Blood · 2011 · 121 citations

Medicine, Oncology, Pharmacotherapy +15

Core-binding factor acute myeloid leukemia in first relapse: a retrospective study from the French AML Intergroup

Thomas Prébet, Sarah Bertoli, Xavier Thomas et al. · Blood · 2014 · 80 citations

Medicine, Hematology, Oncology +14